Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease

Clicks: 474
ID: 116637
1985
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Aerosolized ribavirin was evaluated in the treatment of respiratory syncytial virus lower respiratory tract disease in 53 infants, 36 of whom had underlying diseases. Of the total infants, 26 were studied in a double-blind, placebo-controlled manner; 14 received ribavirin and 12 received placebo, a …
Reference Key
cb1985jamaribavirin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hall CB;McBride JT;Gala CL;Hildreth SW;Schnabel KC;;
Journal JAMA
Year 1985
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/3903239
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE clinical trials as topic humans pubmed abstract nih national institutes of health national library of medicine Infant newborn Clinical Trial Double-Blind Method Random Allocation controlled clinical trial respiratory tract infections / complications microbial sensitivity tests c b hall ribavirin / administration & dosage ribavirin / therapeutic use* respiratory tract infections / drug therapy* respiratory syncytial viruses respirovirus infections / drug therapy* ribonucleosides / therapeutic use* heart defects oxygen / blood pmid:3903239 j t mcbride k c schnabel bronchopulmonary dysplasia / complications* congenital / complications* respirovirus infections / complications ribavirin / adverse effects

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.